Pesquisar
Neuronetics Inc
STIMAdicionar à lista de desejos
1.410USD
+0.060+4.44%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
98.11MValor de mercado
PerdaP/L TTM
Mais detalhes de Neuronetics Inc Empresa
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Informações de Neuronetics Inc
Código da empresaSTIM
Nome da EmpresaNeuronetics Inc
Data de listagemJun 28, 2018
CEOMr. Keith J. Sullivan
Número de funcionários716
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 28
Endereço3222 Phoenixville Pike
CidadeMALVERN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19355
Telefone18776007555
Sitehttps://neurostar.com/neuronetics/
Código da empresaSTIM
Data de listagemJun 28, 2018
CEOMr. Keith J. Sullivan
Executivos da empresa Neuronetics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.06M
+1.46%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
828.78K
+1.03%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
625.02K
+5.80%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
340.45K
+8.81%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
190.35K
+15.76%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
170.89K
+17.56%
Mr. Mark Klausner
Mr. Mark Klausner
Managing Partner
Managing Partner
--
--
Mr. W. Andrew Macan
Mr. W. Andrew Macan
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Avinash N. Amin, M.D.
Dr. Avinash N. Amin, M.D.
Director
Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.06M
+1.46%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
828.78K
+1.03%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
625.02K
+5.80%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
340.45K
+8.81%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
190.35K
+15.76%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
170.89K
+17.56%
Perguntas frequentes
Quem são os cinco principais acionistas de Neuronetics Inc?
Os cinco principais acionistas de Neuronetics Inc são: Mr. Sasha Cucuz
Quantas instituições possuem ações da Neuronetics Inc (STIM)?
Em 2026Q1, 236 instituições possuíam ações da Neuronetics Inc, com valor de mercado aproximado de 47.87M, representando 68.80% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -7188276.00.
Qual é a maior fonte de receita da Neuronetics Inc?
Em 2026Q1, o segmento de negócios Clinic revenue gerou a maior receita para Neuronetics Inc, totalizando 86.98M e representando 58.31% da receita total.